| dc.contributor.author | Unal, S | |
| dc.contributor.author | Hayran, M | |
| dc.contributor.author | Tuncer, S | |
| dc.contributor.author | Gur, D | |
| dc.contributor.author | Uzun, O | |
| dc.contributor.author | Akova, M | |
| dc.contributor.author | Akalin, HE | |
| dc.date.accessioned | 2019-12-10T11:21:03Z | |
| dc.date.available | 2019-12-10T11:21:03Z | |
| dc.date.issued | 1996 | |
| dc.identifier.issn | 0066-4804 | |
| dc.identifier.uri | https://doi.org/10.1128/AAC.40.12.2898 | |
| dc.identifier.uri | http://hdl.handle.net/11655/15426 | |
| dc.description.abstract | In this prospective study of enteric fever, 22 patients received 400 mg of pefloxacin twice daily for 5 days (group A) and 24 received 400 mg of pefloxacin twice daily for 7 days (group B). Causative microorganisms were Salmonella typhi (8 in group A, 11 in group B) and Salmonella paratyphi B (14 in group A, 13 in group B). The clinical cure and bacterial eradication rates were 96% (21 of 22) in group A and 100% in group B. In conclusion, 5-day oral administration of pefloxacin was as effective as 7-day treatment of enteric fever caused by Salmonella spp. | |
| dc.language.iso | en | |
| dc.publisher | Amer Soc Microbiology | |
| dc.relation.isversionof | 10.1128/AAC.40.12.2898 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Microbiology | |
| dc.subject | Pharmacology & Pharmacy | |
| dc.title | Treatment Of Enteric Fever With Pefloxacin For 7 Days Versus 5 Days: A Randomized Clinical Trial | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.relation.journal | Antimicrobial Agents And Chemotherapy | |
| dc.contributor.department | İç Hastalıkları | |
| dc.identifier.volume | 40 | |
| dc.identifier.issue | 12 | |
| dc.identifier.startpage | 2898 | |
| dc.identifier.endpage | 2900 | |
| dc.description.index | WoS | |
